ஃப்ட் பல்கலைக்கழகம் ஆஃப் கேடேநிய News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஃப்ட் பல்கலைக்கழகம் ஆஃப் கேடேநிய. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஃப்ட் பல்கலைக்கழகம் ஆஃப் கேடேநிய Today - Breaking & Trending Today

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study


May 18, 2021
RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, according to findings from Cel-02, a phase IIa study.
Average platelet inhibition 15 minutes after the injection increased across three doses, from 77.5% with the lowest dose to 87.5% with the middle dose and 91.7% with the highest dose (
P = 0.002 for trend), Jurriën ten Berg, MD, PhD (St. Antonius Hospital, Nieuwegein, the Netherlands), reported during the virtual EuroPCR 2021.
RUC-4 was well tolerated among the 27 patients in the trial, with one injection-site reaction and two major bleeds, both related to perforation as the guidewire passed through a side branch of the radial artery. ....

Region Flamande , Kai Zheng , Pascal Vranckx , Davide Capodanno , Phd University Of Catania , Idorsia Pharmaceuticals , Phd Heart Centre Hasselt , Celecor Therapeutics , Antonius Hospital , Willem Bor , Heart Centre Hasselt , கை ஜெங் , டேவிட் காபோடான்னா , ஃப்ட் பல்கலைக்கழகம் ஆஃப் கேடேநிய , அன்டோனியஸ் மருத்துவமனை ,

Elective Revascularization, Better Long-term Survival: Meta-analysis


 
(UPDATED) Looking once again at a question that many cardiologists considered settled, a new meta-analysis suggests that patients with stable coronary artery disease undergoing elective revascularization are at a lower risk of dying from cardiac causes over the long term when compared with patients treated with medical therapy alone.
The findings, presented today as a late-breaking clinical trial at EuroPCR 2021, and simultaneously published in the
European Heart Journal, seem to fly in the face of the randomized ISCHEMIA trial findings, published last year. In this analysis, the benefit appeared directly related to the duration of follow-up, with investigators reporting that the longer the follow-up, the lower the risk of cardiac death and spontaneous MI among those who underwent PCI or CABG surgery. ....

William Boden , Eliano Navarese , Davide Capodanno , Phd University Of Catania , Md Nicolaus Copernicus University , European Heart Journal , Nicolaus Copernicus University , Boston University School , England Healthcare System , European Coronary Surgery Study , Surgery Study , வில்லியம் போடன் , டேவிட் காபோடான்னா , ஃப்ட் பல்கலைக்கழகம் ஆஃப் கேடேநிய , ஐரோப்பிய இதயம் இதழ் , நிக்கோலஸ் கோப்பர்நிக்கஸ் பல்கலைக்கழகம் , போஸ்டன் பல்கலைக்கழகம் பள்ளி , இங்கிலாந்து சுகாதாரம் அமைப்பு , அறுவை சிகிச்சை படிப்பு ,

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI


April 09, 2021
Dropping aspirin soon after PCI seems to be the best strategy for preventing bleeding in high-risk patients with nonvalvular atrial fibrillation (AF), according to a landmark analysis of the RE-DUAL PCI trial.
As reported by TCTMD, RE-DUAL PCI supported moving away from a triple-therapy strategy P2Y12 inhibitor, warfarin, and aspirin in these patients in order to lessen bleeding without increasing the risk of thrombotic events.
The new data in conjunction with the rest of the available evidence, including those from AUGUSTUS, “are pretty clear that that strategy of prolonged triple therapy almost should never be used,” study co-author Deepak L. Bhatt, MD, MPH (Brigham and Women’s Hospital, Boston, MA), told TCTMD. “Our article sort of helps bring some granularity to the sort of minimum duration of aspirin that s probably needed.” ....

New York , United States , Benjamine Peterson , Deepakl Bhatt , Roxana Mehran , Davide Capodanno , Phd University Of Catania , Icahn School , Mount Sinai , Cardiovascular Interventions , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ரோக்ஷணா மெஹ்ரான் , டேவிட் காபோடான்னா , ஃப்ட் பல்கலைக்கழகம் ஆஃப் கேடேநிய , இக்ஹ்ன் பள்ளி , ஏற்ற சினை , இருதய தலையீடுகள் ,

Observational Study Supports Continuing Oral Anticoagulation During PCI


April 06, 2021
For patients sent for an unplanned PCI, a strategy of maintaining oral anticoagulation is not associated with a higher risk of ischemic complications or bleeding when compared with a strategy of interrupting the direct oral anticoagulant (DOAC) or vitamin K antagonist (VKA) a day or two before the procedure, a new observational analysis confirms.
Published in the April 12, 2021, issue of
JACC: Cardiovascular Interventions, the study, drawing on the large SWEDEHEART registry, supports the current recommendations from the European Society of Cardiology (ESC) for uninterrupted oral anticoagulation (U-OAC) in patients with atrial fibrillation, venous thromboembolism, or a mechanical heart valve undergoing unplanned, nonemergent PCI, investigators say. ....

United States , Dimitrios Venetsanos , Dharam Kumbhani , Piera Capranzano , Sanjit Jolly , Bayer Janssen , Bristol Myers Squibb , Dominick Angiolillo , Phd University Of Catania , Md Ut Southwestern Medical Center , American College Of Cardiology , Md Mcmaster University Hamilton Health Sciences , Boehringer Ingelheim , Phd Karolinska Institute University Hospital , Phd University Of Florida College Medicine , European Society Of Cardiology , Cardiovascular Interventions , European Society , Karolinska University Hospital , North American , American College , Medical Center , Hamilton Health Sciences , Florida College , ஒன்றுபட்டது மாநிலங்களில் , தரம் கும்பனி ,